作者
Pierre Bigot, Tarek Fardoun, Jean Christophe Bernhard, Evanguelos Xylinas, Julien Berger, Morgan Rouprêt, Jean-Baptiste Beauval, Samuel Lagabrielle, Souhil Lebdai, Myriam Ammi, Hervé Baumert, Bernard Escudier, Nicolas Grenier, Jean-François Hétet, Jean-Alexandre Long, Philippe Paparel, Nathalie Rioux-Leclercq, Michel Soulié, Abdel-Rahmène Azzouzi, Karim Bensalah, Jean-Jacques Patard
发表日期
2014/2
期刊
World journal of urology
卷号
32
页码范围
109-114
出版商
Springer Berlin Heidelberg
简介
Objective
To assess the effect of neoadjuvant targeted molecular therapies (TMTs) on size and level of inferior vena cava tumor thrombi and to evaluate their impact on surgical management.
Methods
We retrospectively analyzed the data of 14 patients treated for a clear cell renal cell carcinoma with inferior vena cava thrombi by neoadjuvant TMT before nephrectomy. Clinical, pathological and perioperative data were gathered retrospectively at each institution. The primitive tumor size and the thrombus size were defined by computed tomography before TMT. The tumor thrombus level was defined according to the Novick’s classification.
Results
Before TMT, thrombus level was staged I for 1 (7 %), II for 10 (72 %) and III (21 %) for 3 patients. First-line therapy was sunitinib in 11 cases and sorafenib in 3 cases. Median …
引用总数
2014201520162017201820192020202120222023202469111112165813148